Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

about

Porphyria: What Is It and Who Should Be Evaluated?

P2860

Q54941174-A795F209-B982-4A0D-AA4D-515501DEAA27

P2860

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

Item

http://www.wikidata.org/entity/Q39072282

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@en

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@nl

type

Item

label

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@en

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@nl

prefLabel

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@en

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@nl

P1476

Pharmacokinetics and Pharmacod ...... eating Dermatologic Disorders.

@en

P2093

Elisabeth I Minder

http://www.w3.org/2001/XMLSchema#string

Jasmin Barman-Aksoezen

http://www.w3.org/2001/XMLSchema#string

Xiaoye Schneider-Yin

http://www.w3.org/2001/XMLSchema#string

P2860

Autoantibodies against neuropeptides are associated with psychological traits in eating disorders

Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization

Change in moles linked to use of unlicensed "sun tan jab"

4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity

Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease.

Central role of p53 in the suntan response and pathologic hyperpigmentation.

Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria.

The melanotropic peptide, [Nle4,D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation.

Skin pigmentation and pharmacokinetics of melanotan-I in humans.

Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.

P2888

s40262-016-0501-5

P304

815-823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-016-0501-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28063031

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

about

P2860

P2860

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698